Table 4 ADT-treated prostate cancer patients characteristics and clinical and pathological parameters
Characteristics | AR | SRD5A1 | SRD5A2 | SRD5A3 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ADT < 12 Months | P-Valueb | ADT < 12 Months | P-Valueb | ADT < 12 Months | P-Valueb | ADT < 12 Months | P-Valueb | |||||
High (n = 2) | No (n = 2) | High (n = 2) | No (n = 2) | High (n = 2) | No (n = 2) | High (n = 1) | No (n = 3) | |||||
Age | 59.5 ± 0.7 | 58 ± 5.6 | 0.75 | 56.5 ± 3.5 | 61 ± 1.4 | 1 | 56.5 ± 3.5 | 61 ± 1.4 | 1 | 54 | 60.3 ± 1.5 | 0.07 |
T Stages | 0.05 | 0.32 | 0.32 | 0.25 | ||||||||
1 | – | – | ||||||||||
– | – | – | – | – | – | |||||||
2 | 100% | – | 50% | 50% | 50% | 50%% | – | 67% | ||||
3 | – | – | – | – | – | – | – | – | ||||
4 | – | 100% | 50% | 50% | 50% | 50% | 100% | 33% | ||||
Gleason scorea | 0.25 | 0.25 | 0.25 | 0.50 | ||||||||
< 7 | 50% | – | – | 50% | – | 50% | – | 33% | ||||
08–10 | 50% | 100% | 100% | 50% | 100% | 50% | 100% | 67% | ||||
PSA levela | 160.6 (17.9–303.3) | 20.2 (10.1–30.4) | 0.19 | 156.7 (10.1–303.3) | 22.3 (17.9–30.4) | 1 | 156.7 (10.1–303.3) | 22.3 (17.9–30.4) | 1 | 10.1 | 30.4 (17.9–303.3) | 0.5 |
ADT Type | – | – | – | – | ||||||||
Orchyde | 2 | – | 1 | 1 | 1 | 1 | – | 1 | ||||
LHRH agonist + antiandrogen | ||||||||||||
– | 2 | 1 | 1 | 1 | 1 | 1 | 2 | |||||
ADT Treatment Duration | 5 (3–7) | 6 (3–9) | – | 8 (7–9) | 3 | – | 8 (7–9) | 3 | – | 9 | 3 (3–7) | – |